AstraZeneca Finds Two More Potential Partners For Imfinzi
Combo Data At ESMO Supports Use With CD73 And NGK2A Inhibitors
AstraZeneca reported results at ESMO on Imfinzi combined with CD73 inhibitor oleclumab and NGK2A inhibitor monalizumab • Source: Shutterstock 
